drugset / Trial / NCT00790374
BN83495 in Prostate Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the pharmacodynamic profile and safety of BN83495 in patients with prostate cancer with disease progression while on androgen ablative therapy
Timeline
- Start
- 2009-01
- Primary completion
- 2010-10
- Completion
- 2011-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irosustat | Small molecule | 20 mg | Oral |
| Subject | Irosustat | Small molecule | 40 mg | Oral |
| Subject | Irosustat | Small molecule | 60 mg | Oral |